ArticleFrontiers in medicine2026
Clinical characteristics and prognosis of patients with HBV-ACLF versus ALD-ACLF: a retrospective comparative study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the differences in clinical characteristics and prognosis between patients with HBV-ACLF (Hepatitis B Virus-related Acute-on-Chronic Liver Failure) and those with ALD-ACLF (Alcohol-Associated Acute-on-Chronic Liver Failure), and to identify risk factors associated with 90-day mortality in both cohorts. Methods: This study enrolled 56 patients with HBV-ACLF and 83 patients with ALD-ACLF to compare their clinical characteristics and conduct analyses of risk factors associated with 90-day prognosis. Result: Compared with the HBV-ACLF cohort, the ALD-ACLF group exhibited a higher proportion of male patients and a greater prevalence of ascites. Additionally, significant differences were observed in laboratory parameters, with ALD-ACLF patients showing higher levels of WBC (white blood cells), N (neutrophils), and M (monocytes) but lower levels of ALT (alanine aminotransferase), AST (aspartate aminotransferase), ALB (albumin), K (potassium), and Na (sodium) compared to HBV-ACLF patients ( Conclusion: Patients with ALD-ACLF typically present with a higher prevalence of comorbidities, such as ascites and infections, compared to those with HBV-ACLF. However, no significant differences in prognosis were observed between the two cohorts. For HBV-ACLF patients, elevated TBIL and prolonged PT were identified as independent risk factors for 90-day mortality. In contrast, in addition to TBIL and PT, elevated white WBC was also associated with 90-day mortality in ALD-ACLF patients. These findings warrant further validation through multicenter studies with larger sample sizes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.